Pharmacom Labs PHARMA Nan D300 is presented in a 10ml vial and reportedly contains 300 milligrams of nandrolone decanoate per milliliter according to the label and packaging. Samples of this product were purchased from a European-based authorized reseller and internet source between the dates of April 10, 2015 and May 10, 2015. The samples were forwarded and received by the analytical laboratory Simec AG for HPLC-UV testing on May 19, 2015. The quantitative dosage testing report was completed on June 2, 2015. The “quality code” listed on the product was “zpgtek35de”. The quality code was successfully used to authenticate/verify the product on /code.
Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.